公开(公告)号：US20130189226A1

公开(公告)日：2013-07-25

申请号：US13841679

申请日：2013-03-15

Applicant: Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Ling WANG ,  Yong DU ,  Longbin LIU ,  Jing XU ,  Rui ZHANG

Inventor： Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Ling WANG ,  Yong DU ,  Longbin LIU ,  Jing XU ,  Rui ZHANG

IPC: C07K14/56

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inteferon like alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，描述了与天然存在的人类干扰素如α2b（HuIFN-α2b）相比，通过基因改组技术产生的重组蛋白具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US20100129904A1

公开(公告)日：2010-05-27

申请号：US12555762

申请日：2009-09-08

Applicant: Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

Inventor： Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

IPC: C12N5/10 ,  C07H21/04 ,  C12N15/63 ,  C12N1/21

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.